Effective in necrosis and drug accumulation in the tumor

Intraarterial coapplication of carboplatin and DSM increased the tumor concentration of carboplatin.[9]



Figure 6: *Comparison of carboplatin concentration in healthy liver tissue, kidney, and tumor tissue after i.v. carboplatin, i.a. carboplatin and i.a. coapplication of carboplatin and DSM in VX-2 liver tumor-bearing rabbits.*[9]

DSM-TACE **significantly improves** necrotic cell death

Necrotic areas within the tumors increased significantly after application of DSM and DEB in contrast to Lipiodol.[10]



Figure 7: *The effect of Lipiodol, drug-eluting beads (DEB), and degradable starch microspheres (DSM) on necrotic cell death were analyzed in a rat model of colorectal liver metastases*[10]

DSM-TACE quick facts

- Simple application[3]
- Well tolerated[11, 12]
- Boosts tumor necrosis due to temporary ischemia[10]
- Preserves organ function over time[12, 13, 14]
- Degradability of DSM allows vascular reperfusion after ca. 90 minutes[5]
- Can be combined with any chemotherapeutic drug[3]
- Repeated application possible at short intervals[11, 15, 16]

References

1. *Data on file: Product file of EmboCept® S DSM 50 µm*
2. *Hamdi G, Ponchel G, Duchêne D. 2001. J. Microencapsul. 18(3): 373–383. Doi: 10.1080/02652040010019505*
3. *Magle Chemoswed AB. EmboCept® S DSM 50 µm Instruction for use. Date of information: 15.05.2020*
4. *Hamdi G, Pochel G. 1999. Pharm. Res. 16(6):867–875. Doi: 10.1023/a:1018878120100*
5. *Wiggermann P, Wohlgemuth WA, Heibl M et al. 2013. Clin. Hemorheol. Microcirc. 53:337–48. Doi: 10.3233/CH-2012-1555. [A]*
6. *Caine M, Carugo D, Zhang X et al. 2017. Adv. Healthcare Mater. 6(9):1601291. Doi: 10.1002/adhm.201601291 [A]*
7. *Massmann A, Rodt T, Marquardt S et al. 2015. Langenbecks Arch. Surg. 400:641–659. Doi: 10.1007/s00423-015-1308-9 [A, B]*
8. *Rozzanigo U, Gatti F, Luppi G et al. 2023. Hepatoma Res. 9:14. DOI: 10.20517/2394-5079.2022.66 [A, B]*
9. *Pohlen U, Berger G, Binnenhei M et al. 2000. J. Surg. Res. 92(2):165-170. Doi: 10.1006/jsre.2000.5856 [B]*
10. *Ziemann C, Roller J, Malter MM et al. 2019. BMC Cancer 19:938. Doi: 10.1186/s12885-019-6135-x [A]*
11. *Minici R, Ammendola M, Manti F, et al. 2021. Front. Pharmacol. 12:634087. Doi: 10.3389/fphar.2021.634087.*
12. *Vogl TJ, Mekkawy AIA, Thabet DB et al. 2019. Eur. Radiol. 29(4):1939-1949. Doi: 10.1007/s00330-018-5757-8 [A]*
13. *Ludwig JM, Iezzi R, Theysohn JM et al. 2021. Cancers (Basel). 13(20):5122. Doi: 10.3390/cancers13205122 [A]*
14. *Schaarschmidt BM, Slama A, Collaud S et al. 2022. Eur. Radiol. Exp. 6(1):6. Doi: 10.1186/s41747-021-00255-9 [A]*
15. *Orlacchio A, Chegai F, Roma S et al. 2020. Radiol. Med. 125(1):98-106. Doi: 10.1007/s11547-019-01093-x.*
16. *Vogl TJ, Hoppe AT, Gruber-Rouh T et al. 2020. J. Vasc. Interv. Radiol. 31(2):301-310. Doi: 10.1016/j.jvir.2019.08.027 [A]*

[A] Concerns the former products EmboCept® or EmboCept® S, manufactured by Serumwerk Bernburg AG

[B] Concerns the former product Spherex®, manufactured by Pharmacia AB

Magle PharmaCept GmbH, Bessemerstr. 82, 12103 Berlin, Germany
Phone: +49-(0)30–7565985-0 · Fax: +49-(0)30–7565985-11
www.maglepharmacept.com · info@maglepharmacept.com

20230801-01/2023

Effective short-term chemoembolization

EmboCept® S DSM 50 µm:
Degradable starch microspheres (DSM)
for transarterial chemoembolization (TACE)
in liver and lung tumors

EmboCept® S
DSM 50 µm

Characteristics of short-term embolization particles

EmboCept® S DSM 50 µm biodegradable particles

- Produced from hydrolyzed starch[1, 2]
- Can be mixed with various chemotherapies[3]
- Enzymatically degraded by endogenous alpha amylases[1,4]
- Half-life (in vitro): 30-40 minutes[1]



Figure 1: *Scanning electron microscopy picture of EmboCept® S DSM 50 µm microspheres*

Vascular reperfusion after ca. 90 minutes[5]



Figure 2: *Change of regional blood flow (RBF) perfusion parameter from prior DSM-embolization to two hours post DSM-embolization in HCC patients.*

prior = i.a. measurement prior to the DSM-embolization.[5]

post = i.a. measurement immediatelly post DSM-embolization.[5]

Outstanding technical properties for embolization

EmboCept® S DSM 50 µm: the tightest calibrated DSM particles (95% of particles between 20-90 µm in size)[1]



Figure 3: *Particle size distribution curve[1]*

Calibrated Spheres for Optimal Vessel Occlusion



Figure 4: *Tighter calibrated spheres can penetrate deeper into the vasculature[6]*

Indicated for **chemoembolization** of liver and lung tumors

EmboCept® S DSM 50 µm has a broad application range

EmboCept® S DSM 50 µm microspheres are an adjuvant in the intra-arterial treatment of inoperable liver and lung tumors and used in combination with cytostatic agents.[3]

Due to its degradability EmboCept® S DSM 50 µm can be applied for superselective treatments of single-liver segments and used for a selective targeting of one liver lobe to treat multifocal, diffuse tumors and non-visible micro tumors.[7, 8]





Figure 5: *Right and left liver lobe with multifocal and single tumors and selective catheter position of the right liver lobe*